Drugs / iron (III) hydroxide polymaltosate
iron (III) hydroxide polymaltosate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03993288 | Jun 2019 → Jun 2020 | iron deficiency anemia | Sandoz | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iron (III) hydroxide polymaltosate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03993288 ↗ |
| Known as | Ferrum Lek | “Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)” NCT03993288 ↗ |
| Known as | MALTOFER | “MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)” NCT03993288 ↗ |
| Route | Oral | “Subjects in Group 1 received 2 tablets per day (200 mg) of chewable tablets Ferrum Lek® during or immediately after meals; once daily.” NCT03993288 ↗ |